Nigrostriatal dopaminergic neuron

A nigrostriatal dopaminergic neuron is a specialized type of nerve cell that originates in the substantia nigra pars compacta (SNc) and extends its axons to the dorsal striatum (caudate nucleus and putamen). These neurons are fundamental to the basal ganglia's motor loop, where they release dopamine to modulate movement, posture, and motor learning [1][2]. The progressive and selective degeneration of these neurons is the defining pathological feature of Parkinson's disease, leading to the depletion of striatal dopamine and subsequent motor symptoms like tremors and bradykinesia [2][3]. While 'Nigrostriatal neuron' refers to a cellular anatomical unit rather than a single molecular target, it serves as the physiological locus for various drug targets including the dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT2), and dopamine receptors [4][5]. Therapeutic strategies focus on protecting these remaining neurons or replacing the lost dopamine through precursors like levodopa and agonists that mimic its effect on downstream receptors [1][6].

Other names

Nigrostriatal neuronSubstantia nigra pars compacta neuronDA neuronNigrostriatal dopaminergic pathway cell

Pharmacological intervention involves dopamine precursor replacement, inhibition of dopamine degradation (MAO-B and COMT inhibitors), or direct stimulation of post-synaptic dopamine receptors to compensate for the loss of these neurons.